Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 182

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 182
---
 2,305,849  
     -  
     -  
     2,305,849 
  
    Issuance of shares of common stock, net of issuance costs (Note 6b) 
     152,000  
     1,520  
     352,591  
     -  
     -  
     354,111 
  
    Issuance of shares of common stock and warrants, net of issuance costs (Note 6c) 
     1,643,837  
     16,438  
     2,445,532  
     -  
     -  
     2,461,970 
  
    Issuance of shares of common stock and warrants, net of issuance costs (Note 6d) 
     1,817,017  
     18,170  
     1,750,304  
     -  
     -  
     1,768,474 
  
    Net loss 
     -  
     -  
     -  
     (15,022,027) 
     -  
     (15,022,027)
  
    Balance, December 31, 2024 
     12,013,901  
    $120,139  
    $64,263,919  
    $(60,439,183) 
    $-  
    $3,944,875 
  
    Balance 
     12,013,901  
    $120,139  
    $64,263,919  
    $(60,439,183) 
    $-  
    $3,944,875 

See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm

F-5

INDAPTUS
THERAPEUTICS, INC.

Consolidated
Statements of Cash Flows

    2024  
     2023 

    For the year ended December 31, 

    2024  
     2023 
  
    Cash flows from operating activities: 

    Net loss 
    $(15,022,027) 
    $(15,423,471)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation 
     735